Why the study?
Dual antiplatelet treatment with aspirin plus clopidogrel for a limited time is recommended after minor noncardioembolic stroke, prompting evaluation of its efficacy and safety versus monotherapy.
Does dual antiplatelet treatment reduce recurrent stroke and composite cardiovascular events compared with monotherapy in patients with prior stroke or transient ischemic attack?
Population
27 358 patients evaluated for secondary prevention of recurrent stroke or transient ischemic attack
Comparison
DAPT vs monotherapy
Design
Systematic review and meta-analysis of randomized controlled clinical trials
Authors
Loading...
Short-term DAPT reduces recurrent stroke/TIA risk versus monotherapy; reinforces guidelines for minor noncardioembolic stroke.
Does dual antiplatelet treatment reduce recurrent stroke and composite cardiovascular events compared with monotherapy in patients with prior stroke or transient ischemic attack?
DAPT is more effective than monotherapy for secondary stroke prevention but increases major bleeding, a risk that may be mitigated by limiting duration to ≤30 days and avoiding the combination of aspirin plus ticagrelor.
Trifan et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: